Le Lézard
Classified in: Health
Subjects: PET, ANW

Heska Announces Annual Meeting of Stockholders on May 3, 2023


LOVELAND, Colo., April 21, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announces its 2023 Annual Meeting of Stockholders. The virtual event is scheduled for 9 a.m. MT / 11 a.m. ET on Wednesday, May 3, 2023. Stockholders of record as of March 6, 2023, are entitled to notice of, participate in and vote at, the annual meeting. All stockholders are encouraged to vote on the proposed matters before the Annual Meeting by proxy as described in the Company's proxy materials provided to stockholders. 

2023 Annual Meeting of Stockholders
Wednesday, May 3, 2023
9 a.m. MT / 11 a.m. ET

To access the webcast, please visit: http://meetnow.global/M2CPXHH.

About Heska

Heska Corporation (NASDAQ: HSKA) sells, manufactures, markets, and supports diagnostic and specialty products and solutions for veterinary practitioners. Heska's portfolio includes point-of-care diagnostic laboratory instruments and consumables including rapid assay diagnostic products; digital cytology services; point-of-care digital imaging diagnostic products; local and cloud-based data services; practice information management software ("PIMS") and related software and support; reference laboratory testing; allergy testing and immunotherapy; heartworm preventive products; and vaccines. Heska's primary focus is supporting companion animal veterinarians in providing care to their patients. Heska's business is composed of two operating and reportable segments: North America and International. North America consists of the United States, Canada and Mexico. International consists of geographies outside of North America, primarily in Germany, Italy, Spain, France, Switzerland, Australia and Malaysia. The Company's strategic focus on point-of-care diagnostic laboratory and imaging products is included in both segments. The North America segment also includes the contract manufacturing of vaccines and pharmaceutical products and a small veterinary laboratory, and the International segment includes PIMS business and veterinary laboratories. For more information, please visit www.heska.com.

SOURCE Heska Corporation


These press releases may also interest you

at 16:05
Aptose Biosciences Inc. ("Aptose" or the "Company") , a clinical-stage precision...

at 16:05
ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic...

at 16:05
REGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating ResultsAnnounced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024 Mont-Saint-Guibert, Belgium ? May 14, 2024...

at 16:05
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 16:05
BeiGene, Ltd. , a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28...

at 16:05
Akili, Inc. , a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company's board of directors has initiated...



News published on and distributed by: